AFDN
AFDN (Afadin) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Skin cancer, Colorectal cancer and 2 more.
Overview
Belongs to an adhesion system, probably together with the E-cadherin-catenin system, which plays a role in the organisation of homotypic, interneuronal and heterotypic cell-cell adherens junctions (AJs). Nectin- and actin-filament-binding protein that connects nectin to the actin cytoskeleton. May play a key role in the organisation of epithelial structures of the embryonic ectoderm.
Open Targets scores its association with cancer at 0.66 (direct and indirect evidence; datatypes literature 0.94, animal model 0.59, genetic association 0.00, somatic mutation 0.85). IntOGen calls it a driver in 3 cohorts (1 activating, 2 loss-of-function), covering Invasive Breast Carcinoma, Colorectal Adenocarcinoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · AFDN (Afadin) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Skin cancer, Colorectal cancer and 2 more.
- 1 · What it is
AFDN (Afadin) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Skin cancer, Colorectal cancer and 2 more.
- 2 · What goes wrong in cancer
Belongs to an adhesion system, probably together with the E-cadherin-catenin system, which plays a role in the organisation of homotypic, interneuronal and heterotypic cell-cell adherens junctions (AJs).
- 3 · How drugs use it
No product in this corpus aims at AFDN yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
External identifiers
Sources: HGNC HGNC:7137 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P55196 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000130396 (association with cancer (MONDO_0004992) 0.66; per-cancer scores at or above 0.5: colorectal cancer 0.53, melanoma 0.55, skin cancer 0.58, breast cancer 0.57, lung cancer 0.51 (GraphQL API, CC0)); IntOGen AFDN (driver in 3 cohorts (Act 1, LoF 2); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Belongs to an adhesion system, probably together with the E-cadherin-catenin system, which plays a role in the organisation of homotypic, interneuronal and heterotypic cell-cell adherens junctions (AJs). Nectin- and actin-filament-binding protein that connects nectin to the actin cytoskeleton. May play a key role in the organisation of epithelial structures of the embryonic ectoderm. Essential for the organisation of adherens junctions. Location: Cell junction, adherens junction (UniProt). Locus 6q27 (HGNC).
- Breast cancer: Open Targets association 0.57 with breast cancer (MONDO_0007254); IntOGen driver in 2 cohorts (BRCA)
- Skin cancer: Open Targets association 0.58 with skin cancer (MONDO_0002898)
- Colorectal cancer: Open Targets association 0.53 with colorectal cancer (MONDO_0005575); IntOGen driver in 1 cohort (COADREAD)
- Lung cancer: Open Targets association 0.51 with lung cancer (MONDO_0008903)
- Melanoma: Open Targets association 0.55 with melanoma (MONDO_0005105)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 1 cohort; IntOGen calls it a loss-of-function (LoF) driver in 2 cohorts; UniProt disease notes describe a translocation or gene fusion involving the gene. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"AFDN" OR ABSTRACT:"AFDN" OR TITLE:"afadin, adherens junction formation factor" OR ABSTRACT:"afadin, adherens junction formation factor" OR TITLE:"Afadin" OR ABSTRACT:"Afadin" OR TITLE:"AF-6" OR ABSTRACT:"AF-6" OR TITLE:"AF6" OR ABSTRACT:"AF6" OR TITLE:"MLLT4" OR ABSTRACT:"MLLT4") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about AFDN, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetATP2B3
Shares Lung cancer (all types), Skin cancer (all types), Breast cancer (all types), IntOGen.
- TargetAFF4
Shares Lung cancer (all types), Skin cancer (all types), Breast cancer (all types), IntOGen.
- TargetACVR1B
Shares Lung cancer (all types), Skin cancer (all types), Breast cancer (all types), IntOGen.
- TargetFCRL4
Shares Lung cancer (all types), Skin cancer (all types), Breast cancer (all types), IntOGen.
- TargetIKBKB
Shares Lung cancer (all types), Skin cancer (all types), Breast cancer (all types), IntOGen.
- TargetMAP3K13
Shares Lung cancer (all types), Skin cancer (all types), Breast cancer (all types), Melanoma.
- TargetMRTFA
Shares Lung cancer (all types), Skin cancer (all types), Breast cancer (all types), Melanoma.
- TargetSMAD3
Shares Lung cancer (all types), Skin cancer (all types), Breast cancer (all types), IntOGen.